The Companion Animal Healthcare Market size is estimated at USD 17.90 billion in 2024, and is expected to reach USD 27.57 billion by 2029, growing at a CAGR of 9.03% during the forecast period (2024-2029).
The outbreak of the COVID-19 pandemic impacted the animal healthcare market by increasing the costs of animal testing and veterinary care. Supply chain disruptions and shortages of veterinary medicines were observed in several countries, primarily due to the temporary lockdowns of manufacturing sites, export restrictions, and increased demand for medicine for the treatment of COVID-19. For instance, in July 2020, CDC recommended certain guidelines to veterinary professionals for the treatment of companion animals during the COVID-19 pandemic. However, the increasing investment in research and development activities for launching new and innovative products in the animal healthcare market is driving the market. For instance, in July 2021, Merck Animal Health doubled its animal vaccine production capacity in its Kansas manufacturing facility by USD 100 million. This is expected to help the companion animal healthcare market growth over the forecast period.
Certain factors that are contributing to the market growth are the increase in pet adoption, the rise in the number of initiatives by government and animal welfare, as well as advanced technology in animal healthcare.
With the COVID-19 pandemic and the increasing number of work-from-home scenarios, several people have been diagnosed with depression and anxiety because of the social distancing norms, which have increased the adoption of pet animals. For instance, according to the data published by the European Pet Food Industry: Facts and Figures 2022 report, 10,300,000 dogs and 16,700,000 cats were reportedly adopted in Germany in 2021. As per the same source, the percentage of German households owning at least one cat was 21% and one dog was 19% in 2021. This shows that the adoption of cats was higher among the population as compared to dogs.
The rising incidence of cancer, especially in dogs, is anticipated to provide a growth platform for the market. As per the Animal Cancer Foundation, 65 million dogs and 32 million cats are suffering from cancer in the United States as of 2022. Dogs are more prone to suffer from malignant neoplasia (tumor) and lymphoma, as per the American Veterinary Medical Association. The market is supported by numerous health initiatives, especially for cancer treatment, by both government and private organizations.
Furthermore, the growing pet ownership led to the development of some pet monitoring and pet tracking products, that monitor pet activities and take care of animals' health, thereby driving the growth of the studied market. For instance, in January 2022, Tractive, a GPS-based tracking device company launched an LTE GPS tracker for cats. Also, in June 2022, Petlibro launched a new 5L Camera Monitoring Automatic Pet Feeder in its Granary Series. Such developments are expected to further create demand for pet monitoring devices, driving the studied market growth.
However, the use of counterfeit medicines and increasing costs of animal testing and veterinary care are expected to hinder the growth of the companion animal healthcare market over the forecast period.
Vaccines are comprised of viruses, bacteria, or other disease-causing organisms that have been killed or altered so that they cannot cause any disease but can boost immunity. New advanced vaccines have been manufactured containing genetically engineered components derived from those disease agents.
Additionally, the increasing number of cases of rabies across the globe is one of the major factors driving the market's growth over the forecast period. For instance, according to the data published by WHO in May 2021, dogs are the leading cause of human rabies mortality and account for up to 99.0% of all human rabies transmissions. Vaccination is important for companion animals as it not only safeguards them from epidemics but also protects owners in case of any animal bites.
Furthermore, market players are developing and launching new vaccines globally to enhance their market presence, which is also contributing to the segment's growth. For instance, in March 2021, the world's first animal vaccine against the novel coronavirus was registered in Russia, named Carnivac-Cov, which is developed by a unit of Rosselkhoznadzor (Federal Service for Veterinary and Phytosanitary Surveillance). The clinical trials of Carnivac-Cov involved dogs, cats, and other animals.
Also, in June 2022, in India, the Union Minister of Agriculture and farmers' welfare, Shri Narendra Singh Tomar launched animal vaccines and other diagnostic kits developed by the ICAR-National Research Centre on Equines. The Ancovax Vaccine on Equines is an inactivated SARS-CoV-2 Delta (COVID-19) Vaccine for Animals. The immunity induced by Ancovax neutralizes both Delta and Omicron Variants of SARS-CoV-2. The vaccine contains inactivated SARS-CoV-2 (Delta) antigen with Alhydrogel as an adjuvant.
Moreover, in September 2022, Merck Animal Health announced on World Rabies Day that it has donated around five million doses of its NOBIVAC rabies vaccine to help eliminate canine-mediated rabies. Through its Afya Program, Merck donated the vaccines to key partners such as Mission Rabies and Rabies Free Africa, who administer the vaccine to dogs via mass vaccination campaigns across the world. Development such as these ultimately lead to market growth.
Thus, owing to the above-mentioned factors, the studied segment of the companion animal healthcare market is expected to grow significantly over the forecast period.
The growing pet population and an increase in spending on pet care are fueling market growth. For instance, according to the National Pet Owners Survey 2021-2022 conducted by the American Pet Products Association (APPA), 70% of households own a pet in the United States, which equates to 90.5 million homes. In addition, as per APPA, during the 2019-20 period, around 69 million US households owned a dog, and 45.3 million families owned a Cat.
Additionally, the data published by Pet Keen in May 2022 showed that nearly 38% of Canadian households owned a cat while 35% owned a dog in 2021. As per the same source, pet owners in Canada are spending more money on their pets than before, and 17% of owners are willing to spend more than USD 500 every year for their pet's healthcare. This awareness about pet healthcare among pet owners is expected to create demand for products and services available for per-animal healthcare.
Furthermore, the rising number of chronic diseases among pet animals are further creating demand for companion animal healthcare products and diagnostics for disease detection and treatment. For instance, from an article published in September 2021, it has been observed that periodontal disease is a frequent problem seen in veterinary practices; an average prevalence of 9.3 to 18.2% was noticed within the dog population, while the detailed examinations of anesthetized dogs reported a much higher prevalence of the disease, between 44 and 100%. This is expected to create an opportunity for the development of effective therapeutics for pets in the region, thereby propelling the market growth.
Moreover, the increasing research and development for therapeutic products and continuous advancements in technology in companion animal healthcare in the country are other major factors driving the market growth. For instance, in May 2022, Jaguar Health, Inc. launched the Canine Cancer: Take C.H.A.R.G.E. (Canine Health And ReGistry Exchange), a first-of-its-kind national Canine Cancer Registry and Canine Cancer Care Index to provide the veterinary community and dog owners with important incidence and prevalence data to help guide canine cancer diagnosis and treatment decisions. Also, in November 2021, Bayer Canada launched Claro, the only single-dose, veterinarian-administered first-line treatment for canine otitis externa. Claro is used specifically for the treatment of otitis externa in dogs associated with susceptible strains of yeast (Malassezia pachydermatis) and bacteria (Staphylococcus pseudintermedius).
Therefore, owing to the aforesaid factors, the market is expected to witness growth over the forecast period.
This product will be delivered within 2 business days.
The outbreak of the COVID-19 pandemic impacted the animal healthcare market by increasing the costs of animal testing and veterinary care. Supply chain disruptions and shortages of veterinary medicines were observed in several countries, primarily due to the temporary lockdowns of manufacturing sites, export restrictions, and increased demand for medicine for the treatment of COVID-19. For instance, in July 2020, CDC recommended certain guidelines to veterinary professionals for the treatment of companion animals during the COVID-19 pandemic. However, the increasing investment in research and development activities for launching new and innovative products in the animal healthcare market is driving the market. For instance, in July 2021, Merck Animal Health doubled its animal vaccine production capacity in its Kansas manufacturing facility by USD 100 million. This is expected to help the companion animal healthcare market growth over the forecast period.
Certain factors that are contributing to the market growth are the increase in pet adoption, the rise in the number of initiatives by government and animal welfare, as well as advanced technology in animal healthcare.
With the COVID-19 pandemic and the increasing number of work-from-home scenarios, several people have been diagnosed with depression and anxiety because of the social distancing norms, which have increased the adoption of pet animals. For instance, according to the data published by the European Pet Food Industry: Facts and Figures 2022 report, 10,300,000 dogs and 16,700,000 cats were reportedly adopted in Germany in 2021. As per the same source, the percentage of German households owning at least one cat was 21% and one dog was 19% in 2021. This shows that the adoption of cats was higher among the population as compared to dogs.
The rising incidence of cancer, especially in dogs, is anticipated to provide a growth platform for the market. As per the Animal Cancer Foundation, 65 million dogs and 32 million cats are suffering from cancer in the United States as of 2022. Dogs are more prone to suffer from malignant neoplasia (tumor) and lymphoma, as per the American Veterinary Medical Association. The market is supported by numerous health initiatives, especially for cancer treatment, by both government and private organizations.
Furthermore, the growing pet ownership led to the development of some pet monitoring and pet tracking products, that monitor pet activities and take care of animals' health, thereby driving the growth of the studied market. For instance, in January 2022, Tractive, a GPS-based tracking device company launched an LTE GPS tracker for cats. Also, in June 2022, Petlibro launched a new 5L Camera Monitoring Automatic Pet Feeder in its Granary Series. Such developments are expected to further create demand for pet monitoring devices, driving the studied market growth.
However, the use of counterfeit medicines and increasing costs of animal testing and veterinary care are expected to hinder the growth of the companion animal healthcare market over the forecast period.
Companion Animal Healthcare Market Trends
Vaccines Segment is Expected to Grow at a Significant Rate Over the Forecast Period
The vaccines segment is expected to witness significant growth in the companion animal healthcare market over the forecast period owing to factors such as the rising prevalence of zoonotic and chronic diseases, increasing product launches, growing awareness of animal health, rising investments by government bodies and associations, and increasing healthcare expenditure for companion animals.Vaccines are comprised of viruses, bacteria, or other disease-causing organisms that have been killed or altered so that they cannot cause any disease but can boost immunity. New advanced vaccines have been manufactured containing genetically engineered components derived from those disease agents.
Additionally, the increasing number of cases of rabies across the globe is one of the major factors driving the market's growth over the forecast period. For instance, according to the data published by WHO in May 2021, dogs are the leading cause of human rabies mortality and account for up to 99.0% of all human rabies transmissions. Vaccination is important for companion animals as it not only safeguards them from epidemics but also protects owners in case of any animal bites.
Furthermore, market players are developing and launching new vaccines globally to enhance their market presence, which is also contributing to the segment's growth. For instance, in March 2021, the world's first animal vaccine against the novel coronavirus was registered in Russia, named Carnivac-Cov, which is developed by a unit of Rosselkhoznadzor (Federal Service for Veterinary and Phytosanitary Surveillance). The clinical trials of Carnivac-Cov involved dogs, cats, and other animals.
Also, in June 2022, in India, the Union Minister of Agriculture and farmers' welfare, Shri Narendra Singh Tomar launched animal vaccines and other diagnostic kits developed by the ICAR-National Research Centre on Equines. The Ancovax Vaccine on Equines is an inactivated SARS-CoV-2 Delta (COVID-19) Vaccine for Animals. The immunity induced by Ancovax neutralizes both Delta and Omicron Variants of SARS-CoV-2. The vaccine contains inactivated SARS-CoV-2 (Delta) antigen with Alhydrogel as an adjuvant.
Moreover, in September 2022, Merck Animal Health announced on World Rabies Day that it has donated around five million doses of its NOBIVAC rabies vaccine to help eliminate canine-mediated rabies. Through its Afya Program, Merck donated the vaccines to key partners such as Mission Rabies and Rabies Free Africa, who administer the vaccine to dogs via mass vaccination campaigns across the world. Development such as these ultimately lead to market growth.
Thus, owing to the above-mentioned factors, the studied segment of the companion animal healthcare market is expected to grow significantly over the forecast period.
North America Dominates the Market and Expects to do the Same Over the Forecast Period
North America is expected to dominate the companion animal healthcare market over the forecast period owing to factors such as the rising adoption of companion animals, growing awareness among pet owners about pet healthcare and available services, as well as the presence of key market players in the region.The growing pet population and an increase in spending on pet care are fueling market growth. For instance, according to the National Pet Owners Survey 2021-2022 conducted by the American Pet Products Association (APPA), 70% of households own a pet in the United States, which equates to 90.5 million homes. In addition, as per APPA, during the 2019-20 period, around 69 million US households owned a dog, and 45.3 million families owned a Cat.
Additionally, the data published by Pet Keen in May 2022 showed that nearly 38% of Canadian households owned a cat while 35% owned a dog in 2021. As per the same source, pet owners in Canada are spending more money on their pets than before, and 17% of owners are willing to spend more than USD 500 every year for their pet's healthcare. This awareness about pet healthcare among pet owners is expected to create demand for products and services available for per-animal healthcare.
Furthermore, the rising number of chronic diseases among pet animals are further creating demand for companion animal healthcare products and diagnostics for disease detection and treatment. For instance, from an article published in September 2021, it has been observed that periodontal disease is a frequent problem seen in veterinary practices; an average prevalence of 9.3 to 18.2% was noticed within the dog population, while the detailed examinations of anesthetized dogs reported a much higher prevalence of the disease, between 44 and 100%. This is expected to create an opportunity for the development of effective therapeutics for pets in the region, thereby propelling the market growth.
Moreover, the increasing research and development for therapeutic products and continuous advancements in technology in companion animal healthcare in the country are other major factors driving the market growth. For instance, in May 2022, Jaguar Health, Inc. launched the Canine Cancer: Take C.H.A.R.G.E. (Canine Health And ReGistry Exchange), a first-of-its-kind national Canine Cancer Registry and Canine Cancer Care Index to provide the veterinary community and dog owners with important incidence and prevalence data to help guide canine cancer diagnosis and treatment decisions. Also, in November 2021, Bayer Canada launched Claro, the only single-dose, veterinarian-administered first-line treatment for canine otitis externa. Claro is used specifically for the treatment of otitis externa in dogs associated with susceptible strains of yeast (Malassezia pachydermatis) and bacteria (Staphylococcus pseudintermedius).
Therefore, owing to the aforesaid factors, the market is expected to witness growth over the forecast period.
Companion Animal Healthcare Industry Overview
The market for companion animal healthcare is consolidated. It is majorly dominated by a few players, such as Elanco, Zoetis Animal Healthcare, Ceva Sante Animale, Merck, Virbac, and Boehringer Ingelheim Animal Health, among others. The largest share of the market is captured by these global players. However, few companies are penetrating the market currently and are expected to hold a substantial share of the market in the near future.Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION (Market Size by Value - USD million)
6 COMPETITIVE LANDSCAPE
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Elanco Animal Health
- Boehringer Ingelheim Animal Health
- Virbac
- Brilliant Bio Pharma
- Zoetis Inc.
- Phibro Animal Health Corporation
- IDEXX LABORATORIES INC
- Merck & Co., Inc
- Norbrook
- Ceva Sante Animale
Methodology
LOADING...
